Journal of Clinical Medicine (Oct 2023)

Heart Rate Reduction and Outcomes in Heart Failure Outpatients

  • Felix Memenga,
  • Meike Rybczynski,
  • Christina Magnussen,
  • Alina Goßling,
  • Christoph Kondziella,
  • Nina Becher,
  • Peter Moritz Becher,
  • Julia Bernadyn,
  • Filip Berisha,
  • Wiebke Bremer,
  • Christoph Sinning,
  • Stefan Blankenberg,
  • Paulus Kirchhof,
  • Dorit Knappe

DOI
https://doi.org/10.3390/jcm12216779
Journal volume & issue
Vol. 12, no. 21
p. 6779

Abstract

Read online

Aim. Pharmacologic reduction in heart rate with beta-blockers (BB) or ivabradine is associated with improved survival in heart failure (HF) with sinus rhythm. We analyzed the association of different heart rate-reducing drug treatments on outcomes in HF outpatients. Methods. Consecutive patients with HF in sinus rhythm referred to a specialized tertiary service were prospectively enrolled from August 2015 until March 2018. Clinical characteristics were assessed at baseline. We performed Cox regression analyses to examine the effect of the resting heart rate and different heart rate-reducing drug regimens on all-cause mortality and a composite endpoint of “all-cause mortality or heart transplantation” over a mean follow-up of 3.1 years. Results. Of the 278 patients included, 213 (76.6%) were male, the median age was 57.0 years (IQR 49.0–66.1), and 185 (73.7%) had an ejection fraction Conclusion. Our prospective study confirms the association between low heart rate and survival in HF patients receiving various heart rate-reducing medications. We could not identify a specific effect of either regimen.

Keywords